Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children with Differing Responses to Antiretroviral Therapy

Journal of Infectious Diseases

Volumn 214, Issue 2, 2016, Pages 226-236

  Prendergast, Andrew J ^a,b   Szubert, Alexander J ^b   Berejena, Chipo ^d   Pimundu, Godfrey ^e   Pala, Pietro ^h   Shonhai, Annie ^d   Musiime, Victor ^e,f   Bwakura Dangarembizi, Mutsa ^d   Poulsom, Hannah ^c   Hunter, Patricia ^c   Musoke, Philippa ^g   Kihembo, MacKlyn ^f   Munderi, Paula ^h   Gibb, DIana M ^b   Spyer, Moira ^b   Walker, A Sarah ^b   Klein, Nigel ^c   Munderi, P ^a,a   Nahirya Ntege, P ^a   Katuramu, R ^a   Lutaakome, J ^a   Nankya, F ^a   Nabulime, G ^a   Sekamatte, I ^a   Kyarimpa, J ^a   Ruberantwari, A ^a   Sebukyu, R ^a   Tushabe, G ^a   Wangi, D ^a   Musinguzi, M ^a   Aber, M ^a   Matama, L ^a   Nakitto Kesi, D ^a   Kihembo, M ^a   Pala, P ^a   Kaleebu, P ^a   Nassimbwa, S ^a   Senyonga, W ^a   Mugyenyi, P ^a   Musiime, V ^a   Keishanyu, R ^a   Afayo, V D ^a   Bwomezi, J ^a   Byaruhanga, J ^a   Erimu, P ^a   Karungi, C ^a   Kizito, H ^a   Namala, W S ^a   Namusanje, J ^a   Nandugwa, R ^a   Najjuko, T K ^a   Natukunda, E ^a   Ndigendawani, M ^a   Nsiyona, S O ^a   Kibenge, R ^a   Bainomuhwezi, B ^a   Sseremba, D ^a   Tezikyabbiri, J ^a   Tumusiime, C S ^a   Balaba, A ^a   Mugumya, A ^a   Nghania, F ^a   Mwebesa, D ^a   Mutumba, M ^a   Bagurukira, E ^a   Odongo, F ^a   Mubokyi, S ^a   Ssenyonga, M ^a   Kasango, M ^a   Lutalo, E ^a   Oronon, P ^a   Pimundu, G ^a   Nakiire, L ^a   Williams, E D ^a   Senfuma, O ^a   Mugarura, L ^a   Nkalubo, J ^a   Abunyang, S ^a   Denis, O ^a   Lwalanda, R ^a   Nankya, I ^a   Ndashimye, E ^a   Nabulime, E ^a   Mulima, D ^a   Nathoo, K J ^a   Bwakura Dangarembizi, M F ^a   Mapinge, F ^a   Chidziva, E ^a   Mhute, T ^a   Vhembo, T ^a   Mandidewa, R ^a   Chipiti, M ^a   Dzapasi, R ^a   Katanda, C ^a   Nyoni, D ^a   Tinago, G C ^a   Bhiri, J ^a   Mudzingwa, S ^a   Muchabaiwa, D ^a   Phiri, M ^a   Masore, V ^a   Marozva, C C ^a   Maturure, S J ^a   Tsikirayi, S ^a   Munetsi, L ^a   Rashirai, K M ^a   Steamer, J ^a   Nhema, R ^a   Bikwa, W ^a   Tambawoga, B ^a   Mufuka, E ^a   Munjoma, M ^a   Mataruka, K ^a   Zviuya, Y ^a   Berejena, C ^a   Shonshai, A ^a   Kurira, P ^a   Mutasa, K ^a   Kekitiinwa, A ^a   Musoke, P ^a   Bakeera Kitaka, S ^a   Namuddu, R ^a   Kasirye, P ^a   Babirye, A ^a   Asello, J ^a   Nakalanzi, S ^a   Ssemambo, N C ^a   Nakafeero, J ^a   Tikabibamu, J ^a   Musoba, G ^a   Ssanyu, J ^a   Kisekka, M ^a   Gibb, D M ^a   Thomason, M J ^a   Walker, A S ^a   Cook, A D ^a   Szubert, A J ^a   Naidoo James, B ^a   Spyer, M J ^a   Male, C ^a   Glabay, A J ^a   Kendall, L K ^a   Crawley, J ^a,a   Prendergast, A J ^a   MacHingura, I ^a   Ssenyonjo, S ^a   Weller, I ^a   Luyirika, E ^a   Lyall, H ^a   Malianga, E ^a   Mwansambo, C ^a   Nyathi, M ^a   Miiro, F ^a   Kinn, S ^a   McNeil, M ^a   Roberts, M ^a   Snowden, W ^a   Breckenridge, A ^a   Pozniak, A ^a   Hill, C ^a   Matenga, J ^a   Tumwine, J ^a   Tudor Williams, G ^a   Barigye, H ^a   Mujuru, H A ^a   Ndeezi, G ^a   Prendergast, A ^a   Spyer, M ^a   Revill, P ^a   Mabugu, T ^a   Mirimo, F ^a   Walker, S ^a   Sculpher, M J ^a   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^e Joint Clinical Research Centre   (United Kingdom)

^f MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^g Paediatric Infectious Diseases Clinic Baylor Uganda   (Uganda)

^h MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Africa; Children; HIV; Immunosuppression; Inflammation

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; EFAVIRENZ; INTERLEUKIN 6; INTERLEUKIN 7; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; AFRICAN; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILD; CHILDHOOD MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE MARKER; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SCHOOL CHILD; VIRUS LOAD; WORLD HEALTH ORGANIZATION; AFRICA; BLOOD; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS;

AFRICA; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD14; BIOMARKERS; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 84977126604     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw148     Document Type: Article

References (45)

1. World Health Organization (WHO). Global update on the health sector response to HIV, executive summary. Geneva: WHO, 2014. http://www. who. int/hiv/pub/ progressreports/update2014-executive-summary/en/. Accessed 31 July 2014.
2. UNAIDS. The gap report. Geneva: UNAIDS, 2014. http://www. unaids. org/en/ resources/documents/2014. Accessed 22 November 2015.
3. Auld AF, Tuho MZ, Ekra KA, et al. Temporal trends in mortality and loss to follow-up among children enrolled in Cote d'Ivoire's national antiretroviral therapy program. Pediatr Infect Dis J 2014; 33:1134-40.
4. Fenner L, Brinkhof MW, Keiser O, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 2010; 54:524-32.
5. Nugent J, Edmonds A, Lusiama J, et al. Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy in a resource-deprived setting. Pediatr Infect Dis J 2014; 33:1148-55.
6. Vermund SH, Blevins M, Moon TD, et al. Poor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagement. PLos One 2014; 9:e110116.
7. Walker AS, Prendergast AJ, Mugyenyi P, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55:1707-18.
8. Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa. PLoS One 2011; 6:e22706.
9. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-46.
10. French MA, Cozzi-Lepri A, Arduino RC, et al. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS 2015; 29:847-51.
11. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201:1796-805.
12. Koethe JR, Blevins M, Nyirenda C, et al. Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in Zambia. J Int AIDS Soc 2011; 14:19.
13. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
14. Ledwaba L, Tavel JA, Khabo P, et al. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012; 7:e24243.
15. McDonald B, Moyo S, Gabaitiri L, et al. Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses 2013; 29:993-9.
16. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59.
17. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-22.
18. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in Early Life. Front Immunol 2014; 5:391.
19. ARROW Trial Team, Kekitiinwa A, Cook A, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; 381:1391-403.
20. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization; 2006. http://www. who. int/childgrowth/standards/technical-report/ en/. Accessed 28 March 2016.
21. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995; 73:17-24.
22. Prentice LR. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986; 1:1-11.
23. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-89.
24. World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO, 2015. http:// www. who. int/hiv/pub/guidelines/earlyrelease-arv/en/. Accessed 28 March 2016.
25. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254:326-42.
26. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
27. Schacker TW, Nguyen PL, Beilman GJ, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110:1133-9.
28. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014; 505:509-14.
29. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/Bcell stimulatory factor type 2 shares identity with monocyte-derived hepatocytestimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987; 84:7251-5.
30. Ananworanich J, Apornpong T, Kosalaraksa P, et al. Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age. J Allergy Clin Immunol 2010; 126:1294-301.
31. Chougnet C, Fowke KR, Mueller BU, et al. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. AIDS 1998; 12:2397-406.
32. Falcon-Neyra L, Benmarzouk-Hidalgo OJ, Madrid L, et al. No differences of immune activation and microbial translocation among HIV-infected children receiving combined antiretroviral therapy or protease inhibitor monotherapy. Medicine 2015; 94:e521.
33. Freguja R, Gianesin K, Mosconi I, et al. Regulatory T cells and chronic immune activation in human immunodeficiency virus 1 (HIV-1)-infected children. Clin Exp Immunol 2011; 164:373-80.
34. Gesner M, Di John D, Krasinski K, Borkowsky W. Increased soluble CD8 (sCD8) in human immunodeficiency virus 1-infected children in the first month and year of life. Pediatr Infect Dis J 1994; 13:896-8.
35. Kourtis AP, Nesheim SR, Thea D, Ibegbu C, Nahmias AJ, Lee FK. Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. AIDS 2000; 14:2429-36.
36. Mendez-Lagares G, Diaz L, Correa-Rocha R, et al. Specific patterns of CD4-associated immunosenescence in vertically HIV-infected subjects. Clin Microbiol Infect 2013; 19:558-65.
37. Pilakka-Kanthikeel S, Kris A, Selvaraj A, Swaminathan S, Pahwa S. Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting. J Acquir Immune Defic Syndr 2014; 66:16-24.
38. Prendergast A, O'Callaghan M, Menson E, et al. Factors influencing T cell activation and programmed death 1 expression in HIV-infected children. AIDS Res Hum Retroviruses 2012; 28:465-8.
39. Resino S, Seoane E, Gutierrez MD, Leon JA, Munoz-Fernandez MA. CD4(+) Tcell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 42:269-76.
40. Sherman GG, Scott LE, Galpin JS, et al. CD38 expression on CD8(+) T cells as a prognostic marker in vertically HIV-infected pediatric patients. Pediatr Res 2002; 51:740-5.
41. Ssewanyana I, Elrefaei M, Dorsey G, et al. Profile of T cell immune responses in HIV-infected children from Uganda. J Infect Dis 2007; 196:1667-70.
42. Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010; 24:1281-90.
43. Achhra AC, Phillips A, Emery S, et al. Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy. HIV Med 2015; 16:449-54.
44. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228.
45. Trehan I, Goldbach HS, LaGrone LN, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med 2013; 368:425-35.